Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update.
“We remain fully focused on generating first-in-human clinical data from VBP101, our Phase 1/2a clinical trial of VOR33 in patients with relapsed/refractory AML, which will provide important proof of concept for our proprietary platform and has the potential to transform outcomes for patients with blood cancers,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We also continue to make progress on our allogeneic healthy donor-derived CAR-T therapy VCAR33ALLO, which remains on track for IND submission in 1H 2023, and look forward to the opening of our new in-house eHSC and CAR-T clinical manufacturing facility later this year.”
Data showcased at Keystone Symposia demonstrates success of several multiplex editing approaches. Data recently presented at the Keystone Symposia Precision Genome Engineering meeting, April 27-May 1, included two posters and a workshop discussion featuring data on multiplex gene editing in human hematopoietic stem cells using various genome editing technologies including base editing. The data show efficient removal of multiple surface antigens with high on-target editing and undetectable translocations, reinforcing the potential of Vor Bio’s novel platform and approach.
Vor Bio’s in-house clinical manufacturing facility in Cambridge, MA headquarters on-track to become fully operational in 2022. The facility is designed to support clinical manufacturing for both Vor Bio’s eHSC and CAR-T product pipeline and will enable the Company to achieve flexible manufacturing capacity and reduce the time and cost required to manufacture cell therapy clinical candidates.
The Company continues to make progress in manufacturing innovation with several recent and upcoming data presentations.
Links to these presentations are located in the Medical & Scientific Events section of the Company’s website.
VOR33: VOR33 is the Company’s lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. It is designed to replace the standard of care in transplant settings for patients suffering from AML and potentially other blood cancers. VOR33 has been granted Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration.
VCAR33 Programs: The VCAR33 programs are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33, a clinically-validated target for AML. VCAR33ALLO uses allogeneic healthy donor-derived cells and is a newly announced program in which Vor Bio plans to submit an investigational new drug (IND) application in the first half of 2023 to support a Phase 1/2 clinical trial for patients with relapsed/refractory AML.
VOR33 + VCAR33 Treatment System: The combination of VOR33 followed by treatment with VCAR33ALLO in the post-transplant setting may transform patient outcomes and offer the potential for cures for patients that have limited treatment options. The VOR33 + VCAR33 Treatment System utilizes the same healthy donor allogenic cell source for both VOR33 and VCAR33ALLO. The Company’s development pathway for this novel-novel treatment is to collect initial data on VOR33 from the VBP101 clinical trial and initial clinical data from the VCAR33ALLO program prior to IND submission for this Treatment System.
VOR33-CLL1 + VCAR33-CLL1 Treatment System: The Company continues to make progress on preclinical and IND-enabling studies for its multiplex-edited program. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using Vor Bio’s novel eHSC platform, which can be combined with a multi-specific CAR-T approach.
First Quarter 2022 Financial Results
About Vor Bio